IL-17 in the Pathophysiology of Psoriasis
Number of slides: 26
This presentation describes 4 core double-blind, placebo-controlled phase 3 trials with Secukinumab in psoriasis alongside an additional double-blind, comparator-controlled head-to-head trial, with particular focus on data from the ERASURE, FIXTURE and CLEAR efficacy studies.
Number of slides: 23
These slides demonstrate the key role of the cytokine IL-17A in psoriasis immunopathogenesis and how IL-17A inhibition leads to downregulation of expression of proteins associated with psoriatic lesion formation.
Number of slides: 27
A host of psoriasis disease assessment tools have been devised to correlate patient and dermatologist views on each individual case of psoriasis, in order to classify the disease and aid treatment decisions.
Number of slides: 29
Treatment guidelines are outlined in this presentation and the treatment goals sought to lead to best patient outcomes and improved quality of life.